Navigation Links
Schering-Plough Reports Financial Results for First Quarter of 2008
Date:4/23/2008

Administration (FDA) of

a New Drug Application for ZEGERID (omeprazole/sodium bicarbonate) as a

branded over-the-counter product to treat frequent heartburn.

(Announced March 11)

-- The FDA's Advisory Committee on Anesthetics and Life Support

unanimously recommended approval of sugammadex, which if approved would

be the first and only selective relaxant binding agent for use with

surgical anesthesia. (Announced March 11)

-- Announced with Centocor, Inc. submission of a Marketing Authorization

Application to the European Medicines Agency requesting approval of

golimumab as a monthly subcutaneous treatment for adults with

rheumatoid arthritis, psoriatic arthritis and ankylosing spondylitis.

(Announced March 18)

-- Announced the launch of two new sunscreen products with an SPF of 70+,

the highest protection rating available to consumers in a continuous

spray. (Announced March 18)

-- Gained FDA approval of label revisions for PEGINTRON (peginterferon

alfa-2b) and REBETOL (ribavirin, USP) combination therapy for chronic

hepatitis C, recommending weight-based dosing of REBETOL based on

patient body weight. (Announced March 27)

-- The Merck/Schering-Plough joint venture announced results of the

ENHANCE ultrasound imaging trial. (Announced March 30)

-- Announced a major new Productivity Transformation Program (PTP) to

reduce and avoid costs and increase productivity to generate a total of

$1.5 billion in targeted annual savings and synergies. (Announced

April 2)

-- Announced adoption of a new governance requirement to strengthen the

alignment of executives with the interests of shareholders: a two-year

holding period for shares acquired by Executive Management Team members

upon the exercise of stock options. (Announced Apri
'/>"/>

SOURCE Schering-Plough Corporation
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19

Related biology technology :

1. Schering-Plough Schedules Conference Call and Webcast for 2008 First Quarter Earnings
2. Schering-Plough Launches Productivity Transformation Program To Confront New Challenges
3. Centocor, Inc. and Schering-Plough Submit Application Requesting Approval of Golimumab in Europe for the Treatment of Rheumatoid Arthritis, Psoriatic Arthritis and Ankylosing Spondylitis
4. Schering-Plough Announces Filing of U.S. Application for OTC ZEGERID(R)
5. Schering-Plough Reports Financial Results for 2007 Fourth Quarter, Full Year
6. Schering-Plough and OraSure Technologies Sign International Collaboration for Rapid Point-of-Care Oral Hepatitis C Test
7. Schering-Plough Announces Organizational Changes at Schering-Plough Research Institute
8. FDA Grants Priority Review for Schering-Ploughs Peginterferon Alfa-2b for the Adjuvant Treatment of Patients With Stage III Melanoma
9. Schering-Plough Announces Sugammadex New Drug Application Filed in Japan
10. Schering-Plough Announces New Drug Application for Sugammadex Assigned Priority Review Status by U.S. FDA
11. Schering-Plough to Webcast Presentation at Morgan Stanley Pharmaceutical CEOs Unplugged Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/20/2014)... NEW YORK , Oct. 20, 2014 /PRNewswire/ ... of their experimental ZMapp™ antibody therapeutic to fight ... of how difficult and time-consuming the production of ... healthcare market research publisher said that while some ... cycle of this compound, those with industry knowledge ...
(Date:10/20/2014)... 2014 Asterias Biotherapeutics, Inc. (NYSE MKT: ... a Notice of Grant Award (NGA) with the ... 1, 2014.  The NGA provides for the immediate ... of additional grant funds pursuant to the previously ... development of Asterias, product, AST-OPC1. The grant provides ...
(Date:10/20/2014)... 2014 , A major pan-European ... the delivery of care has revealed changing trends in ... in the provision of healthcare services across the continent. ... United European Gastroenterology (UEG), have been announced today and ... of the burden of GI disorders across ...
(Date:10/20/2014)... Oct. 20, 2014 PureTech , a ... big healthcare problems, announced today the closing of ... participation from Invesco Perpetual, a $120 Billion group ... drive PureTech,s existing pipeline forward and to advance ... the scientific creativity to really go for the ...
Breaking Biology Technology:Kalorama: ZMapp Highlights Need For Faster Biopharmaceutical Production 2Kalorama: ZMapp Highlights Need For Faster Biopharmaceutical Production 3Asterias Biotherapeutics Announces Notice of Grant Award with CIRM for Phase 1/2a Clinical Trial of AST-OPC1 in Complete Cervical Spinal Cord Injury 2Asterias Biotherapeutics Announces Notice of Grant Award with CIRM for Phase 1/2a Clinical Trial of AST-OPC1 in Complete Cervical Spinal Cord Injury 3Asterias Biotherapeutics Announces Notice of Grant Award with CIRM for Phase 1/2a Clinical Trial of AST-OPC1 in Complete Cervical Spinal Cord Injury 4Major Survey Reveals Changing Trends and Inequalities in Healthcare Provision for Gastrointestinal Disorders Across Europe 2Major Survey Reveals Changing Trends and Inequalities in Healthcare Provision for Gastrointestinal Disorders Across Europe 3Major Survey Reveals Changing Trends and Inequalities in Healthcare Provision for Gastrointestinal Disorders Across Europe 4Major Survey Reveals Changing Trends and Inequalities in Healthcare Provision for Gastrointestinal Disorders Across Europe 5PureTech Announces Expansion with Oversubscribed $55M Funding Round 2PureTech Announces Expansion with Oversubscribed $55M Funding Round 3PureTech Announces Expansion with Oversubscribed $55M Funding Round 4PureTech Announces Expansion with Oversubscribed $55M Funding Round 5PureTech Announces Expansion with Oversubscribed $55M Funding Round 6
... 30 Cepheid (Nasdaq:,CPHD) will present at the ... Four Seasons Hotel, Boston, September 5 to 7, ... Vice President, Finance and,Chief Financial Officer, John R. ... 7. The webcast, along with accompanying presentation ...
... (Nasdaq: VRNM ), a leading developer of cellulosic ... specialty,enzymes, announced today that Carlos A. Riva, President and ... Cowen and Company Clean,Energy Conference. The presentation is scheduled ... 2007 and will take place at Le Parker Meridien ...
... Advanced Life Sciences,Holdings, Inc. (Nasdaq: ADLS ... CEO will present at the 2007 UBS Global ... Grand Hyatt New York on Wednesday,September 26 at ... A live webcast of the presentation will ...
Cached Biology Technology:Cepheid to Present at Thomas Weisel Partners Healthcare Conference 2Verenium Corporation to Present at the Upcoming Cowen and Company Clean Energy Conference 2Verenium Corporation to Present at the Upcoming Cowen and Company Clean Energy Conference 3Advanced Life Sciences to Present at 2007 UBS Global Life Sciences Conference 2
(Date:10/15/2014)... has admitted Johannes Gutenberg University Mainz (JGU) as ... hub continues to maintain a significant nationwide standing ... "The acceptance of Johannes Gutenberg University Mainz as ... milestone in the national and international competition for ... of Rhineland-Palatinate can be proud that Mainz University ...
(Date:10/15/2014)... , Oct. 15, 2014   Neurotechnology , ... announced the availability of the VeriLook Surveillance ... 3.0 provides real-time biometric face identification using live ... surveillance cameras. The new version not only identifies ... people from objects while they are moving through ...
(Date:10/14/2014)... is how to produce enough food to feed the ... Agriculture Organization of the United Nations predicts that food ... to feed a growing global population, and plants are ... production. Plants—grains, cereals, fruits, vegetables, and more—feed humans ... must tap into our knowledge of how plants work ...
Breaking Biology News(10 mins):Johannes Gutenberg University Mainz joins Germany's Gauss-Allianz as a full member 2Johannes Gutenberg University Mainz joins Germany's Gauss-Allianz as a full member 3VeriLook Surveillance 3.0 SDK Identifies Faces and Moving Objects, Differentiates Pedestrians from Other Moving Objects in Video Surveillance Systems 2VeriLook Surveillance 3.0 SDK Identifies Faces and Moving Objects, Differentiates Pedestrians from Other Moving Objects in Video Surveillance Systems 3Building a bridge from basic botany to applied agriculture 2Building a bridge from basic botany to applied agriculture 3
... London, ON When you think you see a face in ... never seems to be upside down. It turns out the ... been wired not to. Using tests of visual perception and ... University of Western Ontario,s world-renowned Centre for Brain & Mind recently ...
... April 18, 2011 Mention vitamin D-fortified foods and ... with the sunshine vitamin since the 1930s. A new ... Challenges/Chemistry Solutions" podcast series says that vitamin D-fortified bread ... essential nutrient that is difficult to get naturally in ...
... University of Minnesota,s College of Biological Sciences, has been awarded ... Health to direct a large-scale research effort to study a ... viral diseases. The goal of the study will be ... better understand how it interacts with other proteins in human ...
Cached Biology News:U of M scientist gets 5-year, $10 million grant to direct innovative HIV research program 2
...
Experion HighSens chips are the microfluidic chips used to perform high-sensitivity RNA analysis (picogram levels) with the Experion automated electrophoresis system. Each chip has the capacity to ru...
... Mitochondria Derived Activator of Caspase/DIABLO Liquid. ... 7.5 AVOID FREEZE/THAW CYCLES. Amino acid residues 56 ... terminal His•Tag ® sequence was expressed in ... is released along with cytochrome c ...
... Decorin ( Abpromise for all ... Synthetic peptide: IGPEVPDDRDFEPS conjugated to ... of Human Decorin (fragment 36-49 of ... Entrez GeneID: ...
Biology Products: